mdlinx mdlinx
Latest (79) Full Text Articles (1945) Article Summary

New therapies for pneumonia
Current Opinion in Pulmonary Medicine, 03/29/2012

Ricard JD – Several leads have been investigated, targeting adhesion, communication, toxins, virulence factors, direct bacterial killing by bacteriophages, and vaccine strategies. Promising results have been obtained with these different targets, including inhibition of quorum sensing, use of pilicide compounds to inhibit bacterial adhesion, prevention and treatment of Pseudomonas aeruginosa pneumonia by bacteriophages, effective protection against P. aeruginosa lung infection with mucosal vaccination, use of anti–PcrV antibodies in P. aeruginosa–induced sepsis. Expectations are high regarding the translation of these experimental results into true clinical benefits for the patients.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Infectious Disease

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Infectious Disease Articles

Last month's top read Top Articles of 2012

Indexed Journals in Infectious Disease: Journal of Infection, AIDS, American Journal of Infection Controlmore

Other Topics in Infectious Disease

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close